ArticleRSC medicinal chemistry2020
Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
Article in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Neuroprotective Effects and Mechanisms of Carvacrol and Thymol in Alzheimer's Disease: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Rational Design and Greener Synthesis of Selenylated Indolamides as Potential Anti-Alzheimer's Agents.ACS omega · 2025Article
- Eplingiella fruticosa leaf essential oil complexed with β-cyclodextrin exerts a neuroprotective effect in an Alzheimer's disease animal model induced by Streptozotocin.Metabolic brain disease · 2024Article
- Sulfonamide Derivatives: Recent Compounds with Potent Anti-alzheimer's Disease Activity.Central nervous system agents in medicinal chemistry · 2024Review
- Article
- Ileum transcriptional response to prolonged supplementation with phytogenic product containing menthol, carvacrol and carvone.Heliyon · 2022Article
- Antioxidant Activity, Molecular Docking, Quantum Studies andFrontiers in pharmacology · 2021Article
- Neuroprotective effects of carvacrol against Alzheimer's disease and other neurodegenerative diseases: A review.Avicenna journal of phytomedicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five synthetic sulfonamides derived from carvacrol, a natural product and a small molecule with druglike properties, were evaluated with respect to their effects on the cognitive deficits of animals with streptozotocin (STZ)-induced Alzheimer's disease (AD). Memory, ambulation, anxiety and oxidative stress were evaluated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.